Overview

A Trial to Evaluate Safety and Efficacy of Rivaroxaban (COVID-19)

Status:
Terminated
Trial end date:
2021-03-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess safety and clinical efficacy of rivaroxaban in people with mild Coronavirus Disease 2019 who are at increased risk of disease progression.
Phase:
Phase 2
Details
Lead Sponsor:
Bill & Melinda Gates Medical Research Institute
Treatments:
Rivaroxaban